Your browser doesn't support javascript.
loading
Pathogenic monoallelic variants in GLIS3 increase type 2 diabetes risk and identify a subgroup of patients sensitive to sulfonylureas.
Meulebrouck, Sarah; Scherrer, Victoria; Boutry, Raphaël; Toussaint, Bénédicte; Vaillant, Emmanuel; Dechaume, Aurélie; Loiselle, Hélène; Balkau, Beverley; Charpentier, Guillaume; Franc, Sylvia; Marre, Michel; Baron, Morgane; Vaxillaire, Martine; Derhourhi, Mehdi; Boissel, Mathilde; Froguel, Philippe; Bonnefond, Amélie.
Afiliação
  • Meulebrouck S; Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), Université de Lille, Institut Pasteur de Lille, Lille University Hospital, Lille, France.
  • Scherrer V; Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), Université de Lille, Institut Pasteur de Lille, Lille University Hospital, Lille, France.
  • Boutry R; Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), Université de Lille, Institut Pasteur de Lille, Lille University Hospital, Lille, France.
  • Toussaint B; Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), Université de Lille, Institut Pasteur de Lille, Lille University Hospital, Lille, France.
  • Vaillant E; Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), Université de Lille, Institut Pasteur de Lille, Lille University Hospital, Lille, France.
  • Dechaume A; Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), Université de Lille, Institut Pasteur de Lille, Lille University Hospital, Lille, France.
  • Loiselle H; Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), Université de Lille, Institut Pasteur de Lille, Lille University Hospital, Lille, France.
  • Balkau B; Inserm U1018 Clinical Epidemiology, Center for Research in Epidemiology and Population Health, Paris-Saclay University, Paris-Sud University, UVSQ, Villejuif, France.
  • Charpentier G; CERITD (Centre d'Étude et de Recherche pour l'Intensification du Traitement du Diabète), Evry, France.
  • Franc S; CERITD (Centre d'Étude et de Recherche pour l'Intensification du Traitement du Diabète), Evry, France.
  • Marre M; Department of Diabetes, Sud-Francilien Hospital, Paris-Sud University, Corbeil-Essonnes, France.
  • Baron M; Institut Necker-Enfants Malades, Inserm, Université de Paris, Paris, France.
  • Vaxillaire M; Clinique Ambroise Paré, Neuilly-sur-Seine, France.
  • Derhourhi M; Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), Université de Lille, Institut Pasteur de Lille, Lille University Hospital, Lille, France.
  • Boissel M; Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), Université de Lille, Institut Pasteur de Lille, Lille University Hospital, Lille, France.
  • Froguel P; Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), Université de Lille, Institut Pasteur de Lille, Lille University Hospital, Lille, France.
  • Bonnefond A; Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), Université de Lille, Institut Pasteur de Lille, Lille University Hospital, Lille, France.
Diabetologia ; 67(2): 327-332, 2024 Feb.
Article em En | MEDLINE | ID: mdl-38051360
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Células Secretoras de Insulina Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Células Secretoras de Insulina Idioma: En Ano de publicação: 2024 Tipo de documento: Article